The guidelines advised that Hb levels should not exceed 12 g/dL, and that ESAs should be carefully reconsidered in patients with a high risk of thromboembolic events, used with caution in liver disease, and not given to patients with ESA hypersensitivity or poorly controlled hypertension (Schrijvers et al., 2010). This evidence concerns the gene GSTM1 and hypertensive disorder.